Eosinophilic Asthma Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Eosinophilic Asthma pipeline constitutes key companies continuously working towards developing Eosinophilic Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Eosinophilic Asthma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Eosinophilic Asthma Market.

The Eosinophilic Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Eosinophilic Asthma Pipeline Report: https://www.delveinsight.com/sample-request/eosinophilic-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Eosinophilic Asthma treatment therapies with a considerable amount of success over the years.
• Eosinophilic Asthma companies working in the treatment market are Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others, are developing therapies for the Eosinophilic Asthma treatment
• Emerging Eosinophilic Asthma therapies in the different phases of clinical trials are- LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others are expected to have a significant impact on the Eosinophilic Asthma market in the coming years.
• In April 2026, Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company developing a novel class of oral small molecule degrader therapies for immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KT-621. This first-in-class oral STAT6 degrader is being developed for the treatment of moderate to severe eosinophilic asthma. KT-621 is currently under evaluation in two global Phase 2b clinical trials for this indication. Despite the availability of existing asthma treatments, such as inhalers and injectable biologics, there remains a considerable unmet need for safe, effective, and convenient oral treatment options.
• Depemokimab/Exdensur emerged as the most significant recent advancement in eosinophilic asthma, progressing from FDA review acceptance in March 2025 to full FDA approval in December 2025.
• In December 2025, According to a GSK press release, the FDA has approved depemokimab as an add-on maintenance therapy for patients aged 12 years and older with severe eosinophilic asthma. Marketed as Exdensur, depemokimab is administered twice a year and is the first and only ultra-long-acting biologic offering this dosing schedule for this patient population.
• In May 2025, AstraZeneca's triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), achieved its primary goals in two Phase III clinical trials for Eosinophilic Asthma. In the KALOS (NCT04609878) and LOGOS (NCT04609904) studies, Breztri demonstrated statistically significant and clinically meaningful improvements in lung function compared to dual-combination ICS/LABA treatments. These randomized, double-blind trials involved a total of 4,434 patients with uncontrolled Eosinophilic Asthma, aiming to evaluate Breztri as a potential therapeutic option.
• In March 2025, Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company focused on advancing treatments for Eosinophilic Asthma and Chronic Obstructive Pulmonary Disease (COPD), announced encouraging findings from its global Phase 2 trial of rademikibart. Published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), the results highlight the potential of rademikibart as an innovative biologic therapy for individuals with moderate-to-severe uncontrolled Eosinophilic Asthma linked to Type 2 inflammation. The study reported a rapid onset of action, consistent improvements in lung function (FEV1), and notable reductions in the annual rate of Eosinophilic Asthma exacerbations.
• In October 2024, AstraZeneca announced positive top-line results from its Phase IIIb BATURA trial, demonstrating that AIRSUPRA® (a combination of albuterol and budesonide) successfully met its primary endpoint. When used as an as-needed rescue therapy, AIRSUPRA® significantly lowered the risk of severe Eosinophilic Asthma exacerbations compared to albuterol alone. The study involved patients with intermittent or mild persistent Eosinophilic Asthma, including those using short-acting beta2-agonists (SABA), low-dose inhaled corticosteroids (ICS), or leukotriene receptor antagonists (LTRA) for maintenance therapy.
• In September 2024, Kinaset Therapeutics presented two oral sessions and a late-breaking poster at the 2024 European Respiratory Society (ERS) Congress, highlighting the potential of its lead clinical asset, frevecitinib (KN-002), as a promising treatment for individuals with moderate to severe Eosinophilic Asthma and chronic obstructive pulmonary disease (COPD).

Eosinophilic Asthma Overview
Eosinophilic Asthma is a severe type of asthma characterized by high levels of eosinophils (a type of white blood cell) in the airways, leading to chronic inflammation. This condition often causes frequent asthma attacks, breathing difficulties, wheezing, and reduced lung function. It is usually harder to control with standard asthma treatments, and patients may require targeted biologic therapies that specifically reduce eosinophil activity.

Get a Free Sample PDF Report to know more about Eosinophilic Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/eosinophilic-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Eosinophilic Asthma Drugs Under Different Phases of Clinical Development Include:
• LNR 125.38: Lanier Biotherapeutics
• BAT2606: Bio-Thera Solutions
• KN-002: Kinaset Therapeutics
• CM326: CSPC ZhongQi Pharmaceutical Technology
• FB 704A: Oneness Biotech Co., Ltd.
• TQC2731: Chia Tai Tianqing Pharmaceutical Group
• Masitinib: AB Science
• GSK3511294: GlaxoSmithKline

Eosinophilic Asthma Pipeline Therapeutics Assessment
• Eosinophilic Asthma Assessment by Product Type
• Eosinophilic Asthma By Stage and Product Type
• Eosinophilic Asthma Assessment by Route of Administration
• Eosinophilic Asthma By Stage and Route of Administration
• Eosinophilic Asthma Assessment by Molecule Type
• Eosinophilic Asthma by Stage and Molecule Type

DelveInsight's Eosinophilic Asthma Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Eosinophilic Asthma product details are provided in the report. Download the Eosinophilic Asthma pipeline report to learn more about the emerging Eosinophilic Asthma therapies
https://www.delveinsight.com/sample-request/eosinophilic-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Eosinophilic Asthma Therapeutics Market include:
Key companies developing therapies for Eosinophilic Asthma are - Genentech, Inc., GlaxoSmithKline, Kymab, Sanofi, 4D Pharma plc, AstraZeneca, Sinomab, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Cumberland Pharmaceuticals, and others.

Eosinophilic Asthma Pipeline Analysis:
The Eosinophilic Asthma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Eosinophilic Asthma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eosinophilic Asthma Treatment.
• Eosinophilic Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Eosinophilic Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eosinophilic Asthma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Eosinophilic Asthma drugs and therapies
https://www.delveinsight.com/sample-request/eosinophilic-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Eosinophilic Asthma Pipeline Market Drivers
• Increase in the prevalence of Eosinophilic Asthma, development of new and innovative treatment options for severe Eosinophilic Asthma are some of the important factors that are fueling the Eosinophilic Asthma Market.

Eosinophilic Asthma Pipeline Market Barriers
• However, high cost of Eosinophilic Asthma medications, poor adherence to treatment, limited efficacy of existing treatments and other factors are creating obstacles in the Eosinophilic Asthma Market growth.

Scope of Eosinophilic Asthma Pipeline Drug Insight
• Coverage: Global
• Key Eosinophilic Asthma Companies: Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others
• Key Eosinophilic Asthma Therapies: LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others
• Eosinophilic Asthma Therapeutic Assessment: Eosinophilic Asthma current marketed and Eosinophilic Asthma emerging therapies
• Eosinophilic Asthma Market Dynamics: Eosinophilic Asthma market drivers and Eosinophilic Asthma market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.